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Background. Special regulatory role of eicosanoids has been postulated in aspirin-induced asthma. Objective.T oi n v e s t i g a t ee f -
fects of aspirin on exhaled breath condensate (EBC) levels of eicosanoids in patients with asthma. Methods. We determined EBC
eicosanoid concentrations using gas chromatography/mass spectrometry (GC-MS) and high-performance liquid chromatog-
raphy/mass spectrometry (HPLC-MS2) or both. Determinations were performed at baseline and following bronchial aspirin
challenge, in two well-deﬁned phenotypes of asthma: aspirin-sensitive and aspirin-tolerant patients. Results. Aspirin precipitated
bronchial reactions in all aspirin-sensitive, but in none of aspirin-tolerant patients (ATAs). At baseline, eicosanoids proﬁle did
not diﬀer between both asthma groups except for lipoxygenation products: 5- and 15-hydroxyeicosatetraenoic acid (5-, 15-HETE)
which were higher in aspirin-induced asthma (AIA) than inaspirin-tolerant subjects. Following aspirin challenge the total levels
of cysteinyl-leukotrienes (cys-LTs) remained unchanged in both groups. The dose of aspirin had an eﬀect on magnitude of the
response of the exhaled cys-LTs and prostanoids levels only in AIA subjects. Conclusion. The high baseline eicosanoid proﬁling
of lipoxygenation products 5- and 15-HETE in EBC makes it possible to detect alterations in aspirin-sensitive asthma. Cysteinyl-
leukotrienes, and eoxins levels in EBC after bronchial aspirin administration in stable asthma patients cannot be used as a reliable
diagnostic index for aspirin hypersensitivity.
1.Introduction
Exhaled breath condensate (EBC) is a simple, noninvasive
technique for monitoring airway inﬂammation. The mea-
surementofeicosanoidsintheexpiredbreathcondensatehas
proven to be a useful noninvasive method for the assessment
and monitoring of airway inﬂammation in inﬂammatory
diseases such as asthma and other pulmonary diseases [1, 2].
Eicosanoids, including prostaglandins (PGs), thrombox-
ane A2 (TXA2), and leukotrienes (LTs), are lipid mediators
involved in the pathogenesis of asthma. TXA2 is rapidly con-
verted to thromboxane B2 (TXB2), a chemically stable met-
abolite.Thus,thromboxanesynthesisinbiologicaltissueshas
been monitored by measuring TXB2 [1, 2]. Eoxins C4,D 4,
and E4 (EXC4, EXD4, EXE4) are 15-lipoxygenase (15-LO)
analogues of cysteinyl leukotrienes (cys-LTs). Eoxins were
metabolized to eoxin E4 and detectable in EBC [3].
Another group of lipoxygenation products is 5-, 12- and
15-hydroxyeicosatetraenoic acid (5-HETE, 12-HETE, 15-
HETE). Isoeicosanoids or isoprostanes are prostaglandin-
like compounds produced by nonenzymatic lipid peroxi-
dation of arachidonic acid. The 8-isoprostane is the best
biomarker of oxidative stress and lipid peroxidation [1–3].
A special regulatory role of eicosanoids was postulated in
aspirin-induced asthma (AIA) [4–6] .A I Ai sc h a r a c t e r i z e db y
nasal polyps, persistent asthma, and aspirin hypersensitivity
[4]. These nasal/sinus and bronchial syndromes with aspirin
hypersensitivity have been named aspirin-exacerbated respi-
ratory disease (AERD). Indeed, in this distinct asthma phe-
notype [7], observations have accumulated pointing to (1)
overproduction of cysteinyl-leukotrienes (cys-LTs), which
are potent proinﬂamatory mediators and bronchoconstric-
tors [4, 6, 8], (2) upon ingestion of aspirin, cys-LTs are
furtherreleasedinrisingamountsprobablyfromeosinophils2 Journal of Allergy
Table 1: Clinical characteristics of the patients.
AIA (n = 21) ATA (n = 23) P
Age (y) 44.9 ±13.96
39 (34 ÷58)
39.8 ±8.71
39 (32 ÷45) N.S. (0.33)
Female/Male 10/11 15/8 N.S. (0.36)
Duration of asthma (y) 12.36 ±8.07
13 (6÷18)
10.26 ±11.33
7( 1÷17) N.S. (0.19)
Inhaled steroids yes/no 18/3 22/1 N.S. (0.34)
Inhaled steroids (μg/d) ﬂutikason 616.57 ±425.83
500 (500 ÷1000)
726.09 ±667.06
500 (250 ÷1000) N.S. (0.93)
FEV1 baseline (% predicted)
placebo/aspirin day
89.87 ±10.83
90.01 (83.45 ÷95.29)
91.45 ±11.47
91.3 (84.81 ÷102.1) N.S. (0.57)
Total IgE (IU/mL) 115.06 ±111.41
76.3 (42.8 ÷158)
162.86 ±177.82
66.8 (24.1 ÷179) N.S. (0.78)
Skin prick test (n)
positive/negative 10/9 15/8 N.S. (0.53)
Blood eosinophil count 472.67 ±295.39∗
424 (324 ÷513)
248.22 ±173.32∗
232 (119 ÷309) 0.003
Values are expressed as mean ± SD, and median (25% and 75% percentiles).
AIA: aspirin-induced asthma.
ATA: aspirin-tolerant asthma.
and mast cells and this is accompanied by worsening of asth-
matics symptoms [9, 10], (3) depressed prostaglandin E2
(PGE2) production by peripheral blood cells [11], nasal pol-
yps [12, 13], bronchial ﬁbroblasts [14], diminished EP2
receptor on the inﬂammatory cells, and association with EP2
gene polymorphism [15, 16], (4) aspirin-precipitated asth-
matic attacks are not associated with changes in the systemic
prostaglandin E2 production, it might stem from the release
ofPGE2 frominﬂammatorycellsduringtheclinicalreactions
to aspirin [17], (5) both prostaglandin D2 (PGD2) and its
metabolite increase after aspirin-induced bronchoconstric-
tion suggesting that this reaction is associated with mast cell
activation [18–20].
Aspirin-induced changes in the levels of eicosanoids,
suchasprostaglandins (PGs)andcys-LTs,havebeenexamin-
edinvariousbiologicsamples,suchasplasma[19,20],saliva
[19], induced sputum [19, 21], nasal washing ﬂuid [22, 23],
bronchoalveolar lavage [24], and urine [9, 10, 17, 25].
So far, there are few published articles on eicosanoids in
EBC in aspirin-induced-asthma patients [26–28]. These
studies concentrated on baseline levels of eicosanoids in
EBC independent of any steroid therapy used. Interestingly,
one of these studies reported prostaglandins (PGE2,P G F 2α,
9α11βPGF2) and cys-LTs levels in breath condensates in
asthmatic patients after oral aspirin challenge [28]. In
the present study, we focus on exhaled breath condensate
concentrations of eicosanoids following bronchial aspirin
challenge, local administration of aspirin in aspirin-induced
asthma patients.
The aim of this study was to evaluate the changes in
wide eicosanoid spectrum concentrations in EBC during
asthmatic response following aspirin inhalation. We hypoth-
esized that the proﬁle of eicosanoids in EBC after local as-
pirin administrated is markedly diﬀerent in aspirin-induced
asthma patients as compared to asthmatics who toler-
ate aspirin well. These results were validated by speciﬁc
analytical techniques, such as gas chromatography/mass
spectrometry (GC-MS) or by high-performance liquid chro-
matography/mass spectrometry (HPLC-MS).
2.MaterialandMethods
2.1.Subjects. Thestudypopulationconsistedof21asthmatic
patients sensitive to aspirin (AIA) and 23 asthmatics who
tolerated aspirin well (ATA). The diagnosis of asthma was
established according to GINA 2008 update. The patients’
characteristics are presented in Table 1.
The diagnosis of aspirin intolerance was conﬁrmed by
oral aspirin provocation tests, performed during 36 months
preceding the study. All ATA patients occasionally used
aspirinwithoutanyadversereactions.Thepatientshadstable
asthma and their baseline FEV1 was >70% of the predicted
value on the study day. None had experienced an exacerba-
tion or a respiratory tract infection in the 6 weeks preceding
the study. Nearly 70% of ATA patients had intermittent
asthma, 13% mild persistent asthma, and 17% moderate
persistent. In AIA group, 67% of patients had intermittent
asthma, 19% mild persistent asthma, and 14% moderate
persistent asthma. According to Asthma Control Test 33%
of AIA patients and 26% of ATA patients had controlled
asthma, and 33% and 48% had partly controlled asthma,
33% and 26% had uncontrolled asthma, respectively. In ATA
group, 2 patients were current smokers and 3 exsmokers.
There were 7 exsmokers and no current smokers in AIA
group. The average level of FEV1 and FEV1/FVC in AIA
patients was 89.9% and 73.2%, in ATA patients was 91.5%
and 78.5%, respectively.
The subjects were instructed to withhold medications
that decrease bronchial responsiveness prior to aspirin chal-
lenge. Short-acting β2-agonists were not used 8 hours before
thechallenge.Long-actingβ2-agonistsandtheophyllinewereJournal of Allergy 3
Table 2: Eicosanoids values at baseline and following aspirin challenge in AIA and ATA patients. Results of eicosanoids were recalculated as
parts per million (ppm) of palmitic acid (PA).
AIA (n = 21) ATA (n = 23) P (ANOVA)
Baseline Challenge Baseline Challenge After the challenge
PGD2 5.22 ±5.93 4.85 ±3.92 4.71 ±3.38 4.36 ±2.83
0.54 (parts/million of PA) 3.18 3.69 4.27 3.85
GC/MS (1.35 ÷5.85) (1.56 ÷6.99) (2.02 ÷6.37) (1.78 ÷6.31)
PGD2 4.65 ±3.14 3.76 ±2.91 3.85 ±2.06 3.72 ±1.58
Unable (parts/million of PA) 3.56 3.00 2.99 3.33
HPLC/MS/MS (1.93 ÷7.02) (1.81 ÷5.66) (2.11 ÷5.38) (2.47 ÷4.83)
9α11βPGF2 2.20 ±2.01 2.21 ±2.02 0.73 ±0.39 0.79 ±0.44
Unable (parts/million of PA) 1.24 1.30 0.61 0.75
GC/MS (0.27 ÷4.34) (0.28 ÷3.90) (0.45 ÷1.05) (0.45 ÷1.02)
PGF2α 1.67 ±1.59 1.41 ±1.38 1.14 ±1.26 0.99 ±1.18
0.82 (parts/million of PA) 0.97 0.86 0.64 0.49
GC/MS (0.26 ÷2.71) (0.42 ÷2.16) (0.43 ÷1.16) (0.38 ÷1.38)
6-keto-PGF1α 30.23 ±18.50 29.27 ±16.26 27.98 ±24.71 29.64 ±27.20
0.74 (parts/million of PA) 32.15 32.96 16.80 16.12
GC/MS (11.76 ÷45.67) (17.09 ÷37.44) (12.20 ÷39.60) (13.82 ÷41.81)
6-keto-PGF1α 30.51 ±19.45 28.92 ±16.65 26.79 ±23.71 28.77 ±25.48
0.11 (parts/million of PA) 32.08 32.51 15.60 18.15
HPLC/MS/MS (11.13 ÷44.05) (15.78 ÷38.12) (11.91 ÷35.68) (13.20 ÷28.65)
11-dehydro TXB2 19.34 ±10.77 20.16 ±11.23 16.43 ±8.14 17.72 ±9.79
0.82 (parts/million of PA) 21.67 21.40 15.10 15.55
GC/MS (12.18 ÷28.14) (12.25 ÷26.23) (9.77 ÷21.96) (11.74 ÷17.17)
11-dehydro TXB2 18.86 ±10.82 20.50 ±11.95 16.15 ±8.20 16.87 ±8.81
0.66 (parts/million of PA) 19.69 21.48 14.49 14.65
HPLC/MS/MS (9.18 ÷27.50) (11.26 ÷25.83) (9.37 ÷22.04) (10.97 ÷19.78)
LTC4 14.51 ±15.87 15.57 ±36.94∗ 9.76 ±14.06 4.16 ±3.08∗
0.003∗ (parts/million of PA) 9.22 6.61 5.40 3.24
HPLC/MS/MS (2.18 ÷22.31) (2.08 ÷11.50) (2.79 ÷10.84) (1.65 ÷5.84)
LTD4 3.11 ±2.80 2.68 ±2.21 3.31 ±2.59 2.57 ±1.55
0.67 (parts/million of PA) 2.18 2.25 2.68 2.16
HPLC/MS/MS (0.83 ÷4.41) (1.22 ÷3.53) (1.60 ÷4.41) (1.42 ÷3.58)
LTE4 6.14 ±3.79 11.96 ±19.51∗ 5.45 ±2.83 6.47 ±2.57∗
0.03∗ (parts/million of PA) 5.19 6.38 4.88 6.54
HPLC/MS/MS (3.23 ÷8.50) (4.95 ÷14.57) (3.10 ÷7.76) (4.42 ÷7.59)
Total cysLTs 23.40 ±19.22 30.54 ±56.90 18.51 ±15.42 13.20 ±5.41
0.33 (parts/million of PA) 19.74 15.70 14.14 12.94
HPLC/MS/MS (6.67 ÷31.22) (6.68 ÷29.20) (10.95 ÷21.25) (8.17 ÷18.75)
LTB4 154.84 ±187.68 73.88 ±77.38∗ 101.37 ±163.65 70.69 ±73.37
0.03∗ (parts/million of PA) 70.28 50.49 49.72 32.29
HPLC/MS/MS (24.57 ÷168.26) (28.71 ÷86.75) (19.05 ÷126.82) (19.01 ÷91.91)
5H E T E 2 3 .95 ±39.08∗ 11.21 ±11.26 6.08 ±3.83∗ 5.41 ±4.41
Unable (parts/million of PA) 9.98 6.78 4.53 4.22
HPLC/MS/MS (4.71 ÷17.95) (2.92 ÷16.24) (3.82 ÷8.32) (2.63 ÷6.68)
12 HETE 23.58 ±25.35 14.58 ±17.15 9.22 ±6.48 7.17 ±9.85∗
Unable (parts/million of PA) 12.49 6.62 7.93 5.23
HPLC/MS/MS (4.27 ÷32.00) (4.31 ÷15.53) (4.11 ÷12.84) (3.87 ÷6.26)4 Journal of Allergy
Table 2: Continued.
AIA (n = 21) ATA (n = 23) P (ANOVA)
Baseline Challenge Baseline Challenge After the challenge
15 HETE 22.65 ±24.08∗ 14.84 ±9.22 7.73 ±5.52∗ 10.47 ±17.07
0.23 (parts/million of PA) 15.48 12.80 6.72 6.13
HPLC/MS/MS (7.80 ÷24.57) (8.35 ÷15.39) (3.17 ÷11.75) (4.62 ÷11.25)
EXC4 2.72 ±2.45 2.99 ±3.08 2.00 ±1.67 1.99 ±1.69
0.79 (parts/million of PA) 2.09 2.59 1.41 1.61
HPLC/MS/MS (1.17 ÷3.42) (0.65 ÷4.32) (1.09 ÷2.38) (0.68 ÷2.38)
EXD4 2.98 ±2.21 2.77 ±2.52 3.03 ±2.50 2.87 ±2.73
0.69 (parts/million of PA) 2.12 1.97 2.57 2.22
HPLC/MS/MS (0.82 ÷4.57) (1.12 ÷4.13) (0.90 ÷4.09) (0.97 ÷4.46)
EXE4 7.86 ±5.11 8.48 ±16.15 8.09 ±9.65 5.65 ±5.28
0.95 (parts/million of PA) 7.06 3.82 3.79 3.65
HPLC/MS/MS (4.00 ÷11.43) (2.89 ÷7.03) (2.67 ÷12.23) (2.33 ÷8.97)
8-iso-PGF2α 0.73 ±0.40 0.79 ±0.38 0.72 ±0.26 0.82 ±0.32
0.09 (parts/million of PA) 0.68 0.76 0.67 0.73
GC/MS (0.40 ÷1.04) (0.54 ÷1.11) (0.58 ÷0.83) (0.55 ÷1.08)
Median (25% and 75% percentiles).
AIA: aspirin-induced asthma. ATA: aspirin-tolerant asthma. PA: palmitic acid.
∗P-values < 0.05; AIA versus ATA at baseline or after the challenge.
P-values:
∗ AIA versus ATA at baseline.
∗baseline versus challenge in AIA.
∗baseline versus challenge in ATA.
withdrawn for 24 hours. Short-acting antihistamines and
cromones were stopped 5 days before the challenge. Inhaled
steroids were allowed at a dose ≤2000μg budesonide per
day. None of the patients were treated with systemic corti-
costeroids or leukotriene modifying drugs.
Baseline and following bronchial aspirin challenge,
exhaled breath condensate eicosanoids (see Table 2)l e v e l s
were measured in all subjects. The patients gave informed
consent and the study was approved by the University Ethics
Committee.
2.2. Study Design. The single-blind, placebo-controlled
bronchial challenge test with aspirin was carried out during
one day in all study patients [29]. The test began with the
inhalation of 7 breaths of placebo (saline). FEV1 was meas-
uredat10and20minutesafterplaceboinhalation.Thepost-
saline FEV1 obtained at 20 minutes was used as “postsaline
baseline” value.
The consecutive doses of lysine-aspirin were inhaled
every 30 minutes by increasing the concentration of lysine-
aspirin and by changing the number of breaths (increasing
doses of 0.18, 0.36, 0.90, 2.34, 7.20, 16.2, 39.60, 115.20mg, at
0.5 hour intervals, up to the cumulative dose of 181.98mg).
FEV1 wasmeasuredat10,20,and30minutesaftereachdose.
The challenge procedure with aspirin was interrupted, if a
bronchospastic reaction occurred (FEV1 dropped ≥ 20%),
or if the maximum cumulative dose of aspirin was reached.
The cumulative dose of aspirin causing a 20% fall in FEV1
was calculated and recorded as PD20 (provocation dose of
aspirin). FEV1 and extrabronchial symptoms were recorded
at baseline, before the challenge tests, and then every 30
minutes until 6 hours after the last dose of aspirin.
In patients with positive bronchial aspirin challenge
(AIA), exhaled breath condensate samples were collected
for wide eicosanoid spectrum (see Table 2) estimations at
baselineandatthetimeofappearanceofthebronchialsymp-
toms (time 0). In ATA patients, whose aspirin challenge was
negative, exhaled breath condensate samples were collected
at baseline and 0.5 hours after the last aspirin dose, that is,
when the cumulative doses of 181.98mg was reached (time
0).
2.3. Lung Function. Pulmonary function tests were per-
formed on a ﬂow-integrating computerized pneumotacho-
graph (Pneumoscreen, E. Jaeger, Germany).
2.4.ExhaledBreathCondensate(EBC). EBCwascollectedac-
cording to ATS/ERS [1] using ECO Screen instrument of Jae-
ger(GmbHHoechberg,Germany).Followingtidalbreathing
for 15–20min, 1-2mL of clear ﬂuid was collected and im-
mediately deeply frozen.
2.5. Biochemical Assays. Exhaled breath condensate concen-
tration of eicosanoids was measured by gas chromatogra-
phy/mass spectrometry (GC-MS) and by high-performance
liquid chromatography/tandem mass spectrometry (HPLC-
MS2) or both; see Table 2. Results of eicosanoids were
recalculated as parts per million (ppm) of palmitic acid (PA)Journal of Allergy 5
or expressed as picograms per milliliter (pg/mL). Detec-
tion limits for eicosanoids measurements were between
0.17pg/mL for 12-HETE and 0.89pg/mL for PGD2. Intraas-
say coeﬃcients of variance were less than 10% and interassay
coeﬃcients of variance were less than 15%. Accuracy of
measurements were better than 98.7%. Detailed analytical
procedure and deuterated standards used were described
elsewhere [3, 27].
2.6. Statistical Analysis. Summary statistics were expressed
as mean (M), standard deviation (SD), median (Me), and
25% and 75% percentiles. General linear model (GLM)
includingrepeatedmeasuresanalysisofvariance,whichtakes
into account the fact that the outcome measurements are
repeated over time within subject was used for multiple
comparisons. Logarithmic transformation was used when
needed as variance stabilizing transformation. Correlation
between variables was estimated with the Spearman rank
order correlations. A P-value ≤ 0.05 was considered statis-
tically signiﬁcant.
3. Results
3.1. Clinical Reactions. There was no statistical diﬀerence
in the clinical characteristics between patients with aspirin-
induced asthma (positive aspirin challenge test), and those
who tolerated aspirin well (negative aspirin challenge
test) except for blood eosinophil count, Table 1.N o n eo f
the patients developed symptoms after administration of
placebo. In aspirin-sensitive asthmatics, bronchial reactions
developed after 0.18mg in 1 subject, after 0.36mg in 2 sub-
jects, after 0.9mg in 3 subjects, following 2.34mg in 2, after
7.2mg in 5 subjects, after 16.2mg in 4 subjects, following
39.6mg in 2 subjects, and after 115.2mg in 2 subjects. The
mean cumulative dose of aspirin was 32.108mg. All the
symptoms were relieved by short-acting β2-agonists. None
of ATA patients developed any clinical symptoms following
aspirin challenges.
3.1.1. Cyclooxygenase Products
Exhaled Breath Condensate Concentration of Prostanoids. At
baseline (Table 2) ,e x h a l e db r e a t hc o n d e n s a t el ev e l so fP G D 2,
suchasitsmetabolite9α11βPGF2,andPGF 2α,6-keto-PGF1α
andnonenzymaticisomer(8-iso-PGF2),didnotdiﬀersignif-
icantly between the study groups. Statistically, results did not
diﬀer dependently on the methods used (HPLC/MS/MS or
GC/MS) for marking eicosanoids and results shown (ppm of
PA or pg/mL).
Following aspirin administration, no signiﬁcant diﬀer-
ences in EBC levels of PGD2 measured by HPLC/MS/MS
(results were recalculated as ppm of PA) and 9α11βPGF2
measured by GC/MS (results were expressed as ppm of PA)
were found in AIA (P = 0.13 and P = 0.82, resp.) and in
A T As u b j e c t s( P = 0.69 and P = 0.43, resp.). The same
marked result (no diﬀerences) was observed when PGD2 was
measured by GC-MS.
Incaseswhen11-dehydroTXB2 resultedasppmof PA, at
baseline (Table 2) and following aspirin challenge (ANOVA,
P = 0.66) exhaled breath condensate level of 11-dehydro
TXB2 did not diﬀer signiﬁcantly between the study groups.
Negative correlation was founded between provocation
doses of aspirin and exhaled PGD2 and its 9α11βPGF2,
PGF2α, 6-keto-PGF1α, and 11-dehydro TXB2 levels only in
AIA patients.
3.1.2. Lipoxygenation Products
Exhaled Breath Condensate Concentration of Cysteinyl-
Leukotriene (Cys-LTs). At baseline (Table 2), exhaled breath
condensatelevelsofleukotrienesC4,D 4,andE 4 didnotdiﬀer
signiﬁcantly between the AIA and ATA groups (P = 0.43,
P = 0.22, P = 0.79, resp.).
In both study groups, following aspirin challenge, EBC
level of LTC4 decreased signiﬁcantly (ANOVA, P = 0.003).
No signiﬁcant diﬀerences in EBC levels of LTD4 was found in
AIA and in ATA group patients (ANOVA, P = 0.67), where
the level remained unchanged and at a constant. Exhaled
LTE4 after aspirin challenge increased signiﬁcantly in both
study groups (ANOVA, P = 0.03). However, total level of
cys-LTs (the sum of LTC4, LTD4, LTE4) showed no changes
in either group studied. Statistically the results of cys-LTs
in EBC were identical independent of units (measurement)
used (ppm of PA or pg/mL).
The dose of inhaled steroid used by study patients and
FEV1 values had no eﬀect on magnitude of the response of
the cys-LTs and its duration.
Negative correlation was founded between provocation
doses of aspirin and exhaled LTC4 (r =− 0.47, P = 0.04),
LTD4 (r =− 0.46, P = 0.04) and LTE4 (r =− 0.43, P = 0.05)
levels only in AIA patients.
Exhaled Breath Condensate Concentration of Leukotriene B4.
At baseline (Table 2), exhaled breath condensate level of
leukotriene B4 did not diﬀer signiﬁcantly between the AIA
and ATA groups (P = 0.36).
Following aspirin administration, EBC levels of LTB4
decreased signiﬁcantly only in aspirin-sensitive patients
(ANOVA, P = 0.03). No diﬀerences were observed when
LTB4 w a se x p r e s s e da sp g / m L .
Exhaled Breath Condensate Concentration of HETE. At base-
line (Table 2), exhaled breath condensate levels of 5-HETE
and 15-HETE were signiﬁcantly higher in AIA as compared
t oA T Ag r o u p s( P = 0.03, P = 0.001, resp.). Figure 1.
Following bronchial aspirin administration, EBC levels of 5-
and 15-HETE (ANOVA, P = 0.23) remained unchanged in
AIA (P = 0.37 and P = 0.23, resp.) and ATA patients.
At baseline (Table 2), exhaled breath condensate levels of
12-HETE did not diﬀer signiﬁcantly between the AIA and
ATA groups (P = 0.13). Following aspirin administration,
EBC levels of 12-HETE decreased signiﬁcantly only in ATA
group(P = 0.03, due to outliers Wilcoxon Matched pairs test
was used).6 Journal of Allergy
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Figure 1: Eicosanoids’ levels in exhaled breath condensate before and after bronchial aspirin challenge. (a) 5-HETE, (b) 15-HETE, and (c)
12-HETA. AIA: aspirin-induced asthma. ATA: aspirin-tolerant asthma. B: baseline. Ch: challenge.Journal of Allergy 7
Table 3: Eicosanoids values at baseline and following aspirin challenge in AIA and ATA patients. Results of eicosanoids were recalculated as
picograms per milliliter (pg/mL).
AIA (n = 21) ATA (n = 23) P (ANOVA)
Baseline After the challenge Baseline After the challenge After the challenge
PGD2 1.49 ±1.17 1.54 ±1.02 2.35 ±2.06 1.80 ±1.22
0.35 (pg/mL) 1.01 1.21 1.64 1.53
GC/MS (0.82 ÷1,68) (0.79 ÷2.11) (1.09 ÷2.70) (0.85 ÷3.20)
PGD2 1.53 ±0.81 1.14 ±0.58 1.76 ±1.14 1.63 ±0.93
0.05 (pg/mL) 1.39 1.09 1.48 1.45
HPLC (0.93 ÷2.02) (0.67 ÷1.36) (0.99 ÷2.19) (0.80 ÷2.07)
9α11βPGF2 0.48 ±0.33 0.50 ±0.34 0.32 ±0.18 0.31 ±0.17
0.59 (pg/mL) 0.36 0.34 0.29 0.28
GC/MS (0.16 ÷0.69) (0.25 ÷0.75) (0.20 ÷0.35) (0.21 ÷0.38)
PGF2α 0.42 ±0.34 0.40 ±0.35 0.43 ±0.33 0.39 ±0.45
0.82 (pg/mL) 0.28 0.27 0.30 0.23
GC/MS (0.19 ÷0.56) (0.15 ÷0.59) (0.23 ÷0.44) (0.16 ÷0.35)
6-keto-PGF1α 8.94 ±4.30 8.70 ±3.72 9.95 ±4.54 9.55 ±4.19
0.53 (pg/mL) 7.17 7.22 7.48 7.46
GC/MS (6.75 ÷7.79) (7.02 ÷7.62) (7.24 ÷15.02) (7.24 ÷11.49)
6-keto-PGF1α 8.99 ±4.41 8.59 ±3.93 9.69 ±4.37 9.46 ±3.95
0.60 (pg/mL) 7.26 6.96 7.40 7.65
HPLC/MS/MS (6.32 ÷8.41) (6.59 ÷8.54) (7.08 ÷13.54) (7.13 ÷10.27)
11-dehydro TXB2 5.74 ±0.87∗ 5.94 ±0.89 6.52 ±0.92∗ 6.39 ±0.94
0.18 (pg/mL) 5.74 6.17 6.81 6.62
GC/MS (5.14 ÷6.34) (5.16 ÷6.49) (6.35 ÷7.00) (5.70 ÷7.16)
11-dehydro TXB2 5.51 ±0.90∗ 5.96 ±1.11 6.40 ±1.17∗ 6.18 ±1.01
0.03∗ (pg/mL) 5.49 6.03 6.63 6.18
HPLC/MS/MS (4.77 ÷6.16) (5.24 ÷6.55) (6.01 ÷7.03) (5.55 ÷7.09)
LTC4 4.17 ±4.56 3.69 ±7.01 4.35 ±4.57 1.87 ±1.73∗
0.01∗ (pg/mL) 2.30 2.02 2.46 1.06
HPLC/MS/MS (1.23 ÷6.42) (1.13 ÷3.36) (1.05 ÷6.18) (0.59 ÷2.74)
LTD4 0.88 ±0.60 0.85 ±0.59 1.58 ±1.28 1.18 ±0.88
0.16 (pg/mL) 0.69 0.65 1.34 0.95
HPLC/MS/MS (0.43 ÷1.19) (0.50 ÷1.03) (0.55 ÷2.04) (0.41 ÷1.77)
LTE4 2.03 ±0.92 3.20 ±3.63∗ 2.46 ±1.43 2.78 ±1.44∗
0.04∗ (pg/mL) 1.83 2.33 1.93 2.45
HPLC/MS/MS (1.28 ÷2.71) (1.57 ÷3.44) (1.30 ÷3.45) (1.54 ÷3.69)
Total cysLTs 7.30 ±4.98 8.02 ±10.75 8.39 ±5.62 5.83 ±3.40
0.24 (pg/mL) 5.97 6.01 7.24 4.90
HPLC/MS/MS (4.14 ÷9.66) (3.91 ÷6.75) (3.06 ÷12.75) (2.87 ÷8.87)
LTB4 69.09 ±102.42 26.15 ±25.60∗ 54.23 ±99.10 34.81 ±37.83
0.02∗ (pg/mL) 29.66 16.99 27.73 15.35
HPLC/MS/MS (10.26 ÷50.00) (10.41 ÷30.38) (6.40 ÷57.18) (6.37 ÷53.27)
5H E T E 7 .15 ±9.80 3.60 ±2.69 2.75 ±1.94 2.61 ±2.99
0.79 (pg/mL) 2.94 3.41 2.29 1.67
HPLC/MS/MS (1.96 ÷7.41) (1.67 ÷5.29) (1.43 ÷3.12) (0.78 ÷3.00)
12 HETE 6.64 ±6.16 5.85 ±10.45 4.03 ±2.68 3.45 ±6.75∗
0.02∗ (pg/mL) 4.05 2.82 3.10 1.93
HPLC/MS/MS (2.91 ÷7.76) (1.52 ÷4.22) (1.53 ÷5.84) (1.25 ÷2.85)8 Journal of Allergy
Table 3: Continued.
AIA (n = 21) ATA (n = 23) P (ANOVA)
Baseline After the challenge Baseline After the challenge After the challenge
15 HETE 6.99 ±4.87∗ 5.81 ±5.14 3.48 ±2.78∗ 5.29 ±11.76
0.30 (pg/mL) 5.96 4.77 2.95 2.39
HPLC/MS/MS (4.04 ÷8.27) (2.53 ÷6.52) (1.75 ÷3.98) (1.92 ÷2.97)
EXC4 1.05 ±0.82 0.92 ±0.89 0.89 ±0.57 0.83 ±0.73
0.74 (pg/mL) 0.79 0.59 0.80 0.61
HPLC/MS/MS (0.45 ÷ 1.61) (1.18 ÷0.58) (0.36 ÷1.40) (0.25 ÷1.07)
EXD4 1.71 ±2.29 1.78 ±2.82 1.70 ±1.76 1.29 ±1.54
0.909 (pg/mL) 0.73 0.62 1.06 0.74
HPLC/MS/MS (0.30 ÷1.51) (0.24 ÷1.93) (0.27 ÷2.31) (0.39 ÷1.96)
EXE4 5.47 ±8.61 3.68 ±6.01 4.01 ±4.97 2.58 ±2.63
0.07 (pg/mL) 2.15 1.05 1.59 1.35
HPLC/MS/MS (0.97 ÷4.60) (0.71 ÷2.66) (0.89 ÷5.66) (0.72 ÷3.89)
8-iso-PGF2α 0.25 ±0.12∗ 0.28 ±0.21 0.33 ±0.15∗ 0.32 ±0.10
0.92 (pg/mL) 0.20 0.21 0.35 0.34
GC/MS (0.17 ÷0.28) (0.19 ÷0.26) (0.20 ÷0.42) (0.25 ÷0.39)
Median (25% and 75% percentiles).
AIA: aspirin-induced asthma. ATA: aspirin-tolerant asthma.
∗P-values < 0.05; AIA versus ATA at baseline or after the challenge.
P-values:
∗ AIA versus ATA at baseline.
∗baseline versus challenge in AIA.
∗baseline versus challenge in ATA.
The dose of inhaled steroid used by patients and FEV1
values had no eﬀect on magnitude of the response of the 5-
and 15-HETE. At baseline, negative correlation was found
between the doses of steroids and EBC levels of 12-HETE
only in aspirin-sensitive subjects (r =− 0.45, P = 0.04).
The dose of aspirin, had no eﬀect on the magnitude of
response of 5- and 15-HETE.
Exhaled Breath Condensate Concentration of Eoxins. At base-
line and following aspirin challenge, exhaled breath conden-
sate levels of eoxins C4,D 4,a n dE 4 did not diﬀer signiﬁcantly
between the AIA and ATA groups (see Table 2).
At baseline and following aspirin challenge no correla-
tionwasfoundbetweenprovocationdosesofaspirin,inhaled
steroid therapy and FEV1 values, and eoxins EBC levels in
aspirin-sensitive and aspirin-intolerant patients.
4. Discussion
In this study, we used a validated analytic platform [27, 30,
31] to analyze eicosanoids in EBC of asthmatic patients. A
highly sensitive method of gas chromatography/mass spec-
trometry or high-performance liquid chromatography/mass
spectrometry or both were used to measure spectrum of ei-
cosanoids-nonvolatile compounds present in EBC [3, 27,
31]. Novel concepts for the standardization of EBC material
measurementshavebeenintroducedtoobtaincharacteristics
ofeicosanoidpatternsproducedbyasthmaticlungs[27].The
assessment of palmitic acid content in EBC among many
other methods [32] seems to be a convenient solution for
compensating the “dilution factor” [3]. It has recently been
demonstrated that dilution of nonvolatile compounds in
water diﬀers between the subjects by more than 1 order of
magnitude and depends on ventilation mechanics [33, 34].
For that reason, in this paper, data are recalculated as parts
per million of palmitic acid. For better understanding, EBC
eicosanoid levels are given in both applicable units: ppm
of PA (Table 2) and in pg/mL (Table 3) independently of
performed assay.
The aim of this study was to compare a wide proﬁle of
eicosanoids released to the epithelial surface of the asthmatic
lung in subjects with and without aspirin hypersensitivity at
baseline and following bronchial aspirin challenge, most of
them on chronic inhaled steroid therapy. We demonstrated
for the ﬁrst time exhaled eicosanoids following local admin-
istration of aspirin in aspirin-induced asthma patients.
Comparing subjects with AIA and ATA no signiﬁcant
diﬀerences were observed in EBC levels of cyclooxygenase
pathway prostanoid products (PGD2 and its metabolite
9α11βPGF2, PGF2α, 6-keto-PGF1α, and 11-dehydro TXB2)
and nonenzymatic isomer (8-iso-PGF2) in neither baseline
nor after aspirin inhalation. Opposing data has been earlier
reported as lower [28] and other times higher [27] baseline
PGD2 metabolite, namely, 9α,11βPGF2, levels in EBC in AIA
patients. Diﬀerences observed in this previous study between
both asthma phenotypes [27] can possibly be explained by
lowerFEV1 valuesandmoresevereofdiseaseinpatientswith
aspirin hypersensitivity compared to subjects who tolerated
aspirin well. Moreover, a signiﬁcant predictor of decreased
FEV1 was increased 9α,11β-PGF2 only in AIA which didJournal of Allergy 9
not correlate in ATA subjects [27]. In our study, all patients
presented comparable FEV1 values, and most likely, similar
bronchoconstricting eicosanoid levels such as PGD2 and
its metabolite. Mast cells are probably the main source of
PGD2 overproduction. Higher global production of PGD2
metabolite 9α,11βPGF2 was also present in the blood and
urine at baseline in AIA subjects [18, 20]. Concentration
of 9α,11β-PGF2 was not changed by the oral-systemic [28]
and how indicated our data bronchial-local administration
of aspirin.
Our results revealed a signiﬁcant upregulation of some
arachidonate lipoxygenation products in asthmatic subjects
with aspirin hypersensitivity, as manifested by high baseline
levels of 5-, 15-HETE in EBC. This data is consistent with the
latestobservations[27].Theseﬁndingsarerelatedtoanover-
expression of lipoxygenases enzymes, particularly 5- and
15-LO in the asthmatic lung with aspirin hypersensitivity.
These enzymes are expressed in eosinophils, activated ma-
crophages, and also in lymphocytes and mast cells. Kowalski
and colleagues have demonstrated that aspirin triggers
speciﬁc generation of 15-HETE from nasal polyp epithelial
cells [12] and peripheral blood leukocytes [35, 36]f r o m
aspirin-sensitive but not aspirin-tolerant subjects with
asthma/rhinosinusitis. Also, they have demonstrated that
two alternatively spliced variants of COX-1 mRNA present
in human leucocytes may be diﬀerently expressed in patients
with asthma. The relative expression of those variants has
been correlated to aspirin-triggered 15-HETE generation
suggesting association of this phenomenon with the patho-
genesis of aspirin-induced asthma [37].
No elevation of baseline 12-HETE in EBC comparing
AIAandATAsubjectswasobserved.Whereas,afterbronchial
aspirin administration, there was a statistically signiﬁcant
decrease in 12-HETE concentration noted only in ATA
subjects. On that basis, we assume blood platelets, the main
sourceof12-LO,maypossiblyplaysomeroleinpathogenesis
of aspirin hypersensitivity. However, 12-LO was originally
cloned from respiratory epithelia, where 15-LO activity was
also found [38].
Our study did not demonstrated baseline local overpro-
duction of cys-LTs in the airways in AIA and is consistent
with an earlier study [28]. Baseline EBC levels of LTC4,
LTD4,a n dL T E 4 did not diﬀer between aspirin tolerant and
hypersensitive subjects. Contrary to this ﬁnding in subjects
with AIA, a higher baseline level of cys-LTs in EBC was also
reported [26, 27]. This might have been a result of low FEV1
values and minor control of asthma (severity index) [27]
or steroid-naive [26] in aspirin hypersensitivities compared
to aspirin tolerant subjects. The levels of exhaled cys-LTs
were lower in those AIA subjects who received inhaled
steroid therapy [26]. Following bronchial aspirin challenge
levels of particular cys-LTs showed some variations but the
total concentration of cys-LTs remained unchanged in both
study groups. Up till now, cys-LTs level in EBC has not
been measured after local (inhaled) aspirin administration.
However, it has been shown [28] that cys-LTs levels in
EBC after oral (systemic administration) aspirin challenge
increased signiﬁcantly in subjects with AIA. Varying results
of diﬀerent studies implicate that levels of cys-LTs in EBC
cannot be a convenient indicator of asthma phenotype as
their level after challenge test possibly depends on manner
of aspirin administration and probably the doses of steroids
inhaled. Results can be surprising because, a key enzyme—
LTC4 synthase, is overexpressed in bronchial mucosa of pa-
t i e n tw i t hA I A[ 39]. Furthermore, circulating steroid blood
eosinophils—main source of LTE4—carry more mRNA
transcripts for this enzyme [40].
As was reported in childhood asthma [41]a n da d u l t
asthmatics [27], 15-LO analogues of cys-LTs, eoxins C4,D 4,
and E4, showed no increase at baseline in asthmatic subjects
independent of aspirin hypersensitivity. Their concentra-
tions were not changed by the bronchial aspirin challenge.
Role of those eicosanoids has been recently investigated in
aspirin hypersensitive patients.
The high-sensitivity eicosanoid proﬁling of lipoxygena-
tion products (5HETE, 15HETE) in EBC makes it possible
to detect alterations in asthma, especially in its distinct phe-
notype characterized by hypersensitivity to aspirin and other
nonsteroidalanti-inﬂammatorydrugs.Cysteinyl-leukotriene
levelsinEBCafteraspirinchallengeinstableasthmapatients,
not steroid naive, most probably cannot be used as a reliable
and sensitive index for aspirin hypersensitivity. In stable AIA
patients on chronic inhaled steroid therapy of global (uri-
nary) rather than in local (breath condensate) production
of postchallenge cys-LTs is of greater and more sensitive
value for aspirin hypersensitivity. We believe that quantitate
cell analysis and measurements of released eicosanoides in
induced-sputum will be more applicable for that purpose.
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